Design, Synthesis, In Silico Docking, Multitarget Bioevaluation and Molecular Dynamic Simulation of Novel Pyrazolo[3,4-d]Pyrimidinone Derivatives as Potential In Vitro and In Vivo Anti-Inflammatory Agents
Pharmaceuticals · 04.09.2025 · 18 (9) · 1326
DOI: 10.3390/ph18091326 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 04.09.2025. Verfasst von Mostafa Roshdi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
A novel series of pyrazolo[3,4-d]pyrimidinone derivatives were synthesized, characterized, and examined for their anti-inflammatory effects.
Results
The findings indicated that compounds 5d, 5j, 5k, and 5m demonstrated significant anti-inflammatory effects through the selective inhibition of the COX-2 isozyme, with IC50 values ranging from 0.27 to 2.34 μM, compared to celecoxib (IC50 = 0.29 μM). Compound 5k emerged as the most potent, exhibiting a selectivity index (SI) of 95.8 for COX-2 relative to COX-1. In vivo tests additionally validated that compounds 5j and 5k demonstrated significant anti-inflammatory efficacy, exhibiting greater suppression percentages of generated paw edema than indomethacin, comparable to celecoxib, while preserving excellent safety profiles with intact gastric tissue. Mechanistic studies demonstrated that the anti-inflammatory efficacy of the target compounds was associated with a substantial decrease in serum levels of TNF-α and IL-6. Moreover, molecular modeling investigations corroborated the in vitro findings. Compound 5k displayed a binding free energy ΔG of −10.57 kcal/mol, comparable to that of celecoxib, which showed a ΔG of −10.19 kcal/mol. The intensified binding contacts in the COX-2 isozyme indicated the augmented inhibitory efficacy of 5k.
Conclusions
Compound 5k exhibited dual activity by inhibiting the COX-2 isozyme and suppressing the pro-inflammatory cytokines TNF-α and IL-6, therefore providing a remarkable anti-inflammatory effect with increased therapeutic potential.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
- Department of Medicinal Chemistry, Faculty of Pharmacy, Merit University, Sohag 82755, Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, Sohag 82524, Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, New Valley University, Al-Kharga 72511, Egypt.
- Medicinal Chemistry Department, Faculty of Pharmacy, Minia National University, New Minia 61768, Egypt.
- Department of Histology and Cell Biology, Faculty of Medicine, Sohag University, Sohag 82524, Egypt.
ORCID-Profile: Mamdouh F A Mohamed, Hossameldin A Aziz, Sahar M Gebril, Stefan Bräse, Aliaa M Mohassab
Zitieren
APA
Roshdi, M., Mohamed, M. F. A., Beshr, E. A. M., Aziz, H. A., Gebril, S. M., Bräse, S., & Mohassab, A. M. (2025). Design, Synthesis, In Silico Docking, Multitarget Bioevaluation and Molecular Dynamic Simulation of Novel Pyrazolo[3,4-d]Pyrimidinone Derivatives as Potential In Vitro and In Vivo Anti-Inflammatory Agents. Pharmaceuticals, 18(9), 1326. https://doi.org/10.3390/ph18091326
Vancouver
Roshdi M, Mohamed MFA, Beshr EAM, Aziz HA, Gebril SM, Bräse S, et al. Design, Synthesis, In Silico Docking, Multitarget Bioevaluation and Molecular Dynamic Simulation of Novel Pyrazolo[3,4-d]Pyrimidinone Derivatives as Potential In Vitro and In Vivo Anti-Inflammatory Agents. Pharmaceuticals. 2025;18(9):1326. doi:10.3390/ph18091326
BibTeX
@article{Roshdi2025,
author = {Roshdi, Mostafa and Mohamed, Mamdouh F A and Beshr, Eman A M and Aziz, Hossameldin A and Gebril, Sahar M and Bräse, Stefan and Mohassab, Aliaa M},
title = {Design, Synthesis, In Silico Docking, Multitarget Bioevaluation and Molecular Dynamic Simulation of Novel Pyrazolo[3,4-d]Pyrimidinone Derivatives as Potential In Vitro and In Vivo Anti-Inflammatory Agents},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {9},
pages = {1326},
doi = {10.3390/ph18091326}
}
EUVIMED